Wissenschaftliche Veröffentlichungen der Gefäßklinik (Auswahl)

  1. Weitz JI, Lensing AWA, Prins MH, Bauersachs R, Beyer-Westendorf J, Bounameaux H, Brighton TA, Cohen AT, Davidson BL, Decousus H, Freitas MCS, Holberg G, Kakkar AK, Haskell L, van Bellen B, Pap AF, Berkowitz SD, Verhamme P, Wells PS, Prandoni P. Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. N Engl J Med. 2017 Mar 30;376(13):1211-22.2017/03/21.
  2. Mazzolai L, Aboyans V, Ageno W, Agnelli G, Alatri A, Bauersachs R, Brekelmans MP, Buller HR, Elias A, Farge D, Konstantinides S, Palareti G, Prandoni P, Righini M, Torbicki A, Vlachopoulos C, Brodmann M. Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European society of cardiology working groups of aorta and peripheral circulation and pulmonary circulation and right ventricular function. Eur Heart J. 2017 Feb 17.2017/03/23.
  3. Martinez-Zapata MJ, Mathioudakis AG, Mousa SA, Bauersachs R. Tinzaparin for Long-Term Treatment of Venous Thromboembolism in Patients With Cancer. Clin Appl Thromb Hemost. 2017 Jan 01:1076029617696581.2017/03/16.
  4. Koscielny J, von Heymann C, Bauersachs R, Mouret P, Antz M. [Perioperative anticoagulation with NOAC using the example of rivaroxaban]. MMW Fortschr Med. 2017 Mar;159(Suppl 4):18-23.2017/03/01.
  5. Khorana AA, Kamphuisen PW, Meyer G, Bauersachs R, Janas MS, Jarner MF, Lee AY. Tissue Factor As a Predictor of Recurrent Venous Thromboembolism in Malignancy: Biomarker Analyses of the CATCH Trial. J Clin Oncol. 2017 Apr 01;35(10):1078-85.2016/12/29.
  6. Farge D, Bounameaux H, Bauersachs RM, Brenner B. Women, thrombosis, and cancer: A gender-specific analysis. Thromb Res. 2017 Mar;151 Suppl 1:S21-S9.2017/03/07.
  7. Cohen AT, Gitt AK, Bauersachs R, Fronk EM, Laeis P, Mismetti P, Monreal M, Willich SN, Bramlage P, Agnelli G, Prefer In Vte Scientific Steering C, The Prefer In Vte Investigators O. The management of acute venous thromboembolism in clinical practice. Results from the European PREFER in VTE Registry. Thromb Haemost. 2017 Jun 27;117(7):1326-37.2017/04/14.
  8. Beyer-Westendorf J, Schellong SM, Gerlach H, Rabe E, Weitz JI, Jersemann K, Sahin K, Bauersachs R. Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial. Lancet Haematol. 2017 Mar;4(3):e105-e13.2017/02/22.
  9. Bauersachs R, Koitabashi N. Overview of Current Evidence on the Impact of the Initial High Dose of the Direct Factor Xa Inhibitor Rivaroxaban on Thrombus Resolution in the Treatment of Venous Thromboembolism. Int Heart J. 2017 Feb 07;58(1):6-15.2017/01/27.
  10. Bauersachs R, Gerlach HE, Heinken A, Hoffmann U, Langer F, Noppeney T, Pittrow D, Klotsche J, Rabe E. Rationale, design, and methodology of the observational INSIGHTS-SVT study on the current state of care and outcomes of patients with superficial vein thrombosis. J Vasc Surg Venous Lymphat Disord. 2017 Jul;5(4):553-60 e1.2017/06/19.
  11. Bauersachs R, Agnelli G, Gitt AK, Monreal M, Mismetti P, Willich SN, Laeis P, Fronk EM, Bramlage P, Cohen AT. The role of heparin lead-in in the real-world management of acute venous thromboembolism: The PREFER in VTE registry. Thromb Res. 2017 Sep;157:181-8.2017/08/07.
  12. Wilke T, Bauer S, Mueller S, Kohlmann T, Bauersachs R. Patient Preferences for Oral Anticoagulation Therapy in Atrial Fibrillation: A Systematic Literature Review. Patient. 2016 Jul 26.2016/07/28.
  13. Werth S, Bauersachs R, Gerlach H, Rabe E, Schellong S, Beyer-Westendorf J. Superficial vein thrombosis treated for 45 days with rivaroxaban versus fondaparinux: rationale and design of the SURPRISE trial. J Thromb Thrombolysis. 2016 Aug;42(2):197-204.2016/03/15.
  14. Linnemann B, Scholz U, Rott H, Halimeh S, Zotz R, Gerhardt A, Toth B, Bauersachs R. Treatment of pregnancy-associated venous thromboembolism - position paper from the Working Group in Women's Health of the Society of Thrombosis and Haemostasis (GTH). Vasa. 2016;45(2):103-18.2016/04/09.
  15. Linnemann B, Bauersachs R, Rott H, Halimeh S, Zotz R, Gerhardt A, Boddenberg-Patzold B, Toth B, Scholz U. Diagnosis of pregnancy-associated venous thromboembolism - position paper of the Working Group in Women's Health of the Society of Thrombosis and Haemostasis (GTH). Vasa. 2016;45(2):87-101.2016/04/09.
  16. Krabbe B, Bauersachs RM. [Bridging in patients with long-term oral anticoagulation - new recommendations]. Dtsch Med Wochenschr. 2016 Feb;141(3):157-60.2016/01/19.
  17. Haas S, Kreutz R, Beyer-Westendorf J, Gebel M, Herold J, Schneider J, Weyrauch P, Bauersachs R, For The XALIA-Study Group in Germany. Prospective, Non-Interventional Study With Rivaroxaban Or Standard Of Care Anticoagulation For Initial Therapy And Secondary Prevention Of Deep Vein Thrombosis – Subgroup Analysis Of Patients In Germany (Xalia-De). 60th Annual Meeting of the German Society of Thrombosis and Haemostasis Research, Münster, 17-20 February 2016: HOTLINE SESSION. 2016.
  18. Cheung YW, Middeldorp S, Prins MH, Pap AF, Lensing AW, Ten Cate-Hoek AJ, Villalta S, Milan M, Beyer-Westendorf J, Verhamme P, Bauersachs RM, Prandoni P. Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep-vein thrombosis. A post-hoc analysis. Thromb Haemost. 2016 Sep 27;116(4):733-8.2016/09/02.
  19. Brekelmans MP, Bleker SM, Bauersachs R, Boda Z, Buller HR, Choi Y, Gallus A, Grosso MA, Middeldorp S, Oh D, Raskob G, Schwocho L, Cohen AT. Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists. Thromb Haemost. 2016 Jul 4;116(1):155-61.2016/03/25.
  20. Bauersachs RM. LMWH in cancer patients with renal impairment - better than warfarin? Thromb Res. 2016 Apr;140 Suppl 1:S160-4.2016/04/14.
  21. Bauersachs R. Katheter-assoziierte Thromboseneigungen. Lindhoff-Last E, Kemkes-Matthes B, Oldenburg J, Tiede A, editors. Wiesbaden: med publico GmbH; 2016.
  22. Bauersachs R. Non-vitamin K antagonist oral anticoagulants for the prevention of recurrent venous thromboembolism. Thromb Res. 2016 Aug;144:12-20.2016/06/06.
  23. Barco S, Lankeit M, Binder H, Schellong S, Christ M, Beyer-Westendorf J, Duerschmied D, Bauersachs R, Empen K, Held M, Schwaiblmair M, Fonseca C, Jimenez D, Becattini C, Quitzau K, Konstantinides S. Home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban. Rationale and design of the HoT-PE Trial. Thromb Haemost. 2016 Jul 4;116(1):191-7.2016/03/25.
  24. Schleussner E, Kamin G, Seliger G, Rogenhofer N, Ebner S, Toth B, Schenk M, Henes M, Bohlmann MK, Fischer T, Brosteanu O, Bauersachs R, Petroff D. Low-molecular-weight heparin for women with unexplained recurrent pregnancy loss: a multicenter trial with a minimization randomization scheme. Ann Intern Med. 2015 May 5;162(9):601-9.2015/05/06.
  25. Lee AY, Kamphuisen PW, Meyer G, Bauersachs R, Janas MS, Jarner MF, Khorana AA. Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial. JAMA. 2015 Aug 18;314(7):677-86.2015/08/19.
  26. Bottger B, Thate-Waschke IM, Bauersachs R, Kohlmann T, Wilke T. Preferences for anticoagulation therapy in atrial fibrillation: the patients' view. J Thromb Thrombolysis. 2015 Aug 11.2015/08/12.
  27. Bauersachs RM, Lensing AW, Prins MH, Kubitza D, Pap AF, Decousus H, Beyer-Westendorf J, Prandoni P. Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment. Thromb J. 2015;12:25.2014/01/01.
  28. Bauersachs RM. Guidelines for the management of cancer and thrombosis - Special aspects in women. Thromb Res. 2015 Feb;135 Suppl 1:S16-22.2015/04/24.
  29. Bauersachs R, Krabbe B. Deep Vein Thrombosis. In: Lanzer P, editor. PanVascular Medicine. Heidelberg New York Dordrecht London: Springer; 2015. p. 4455-82.
  30. Schmitz-Rixen T, Adili F, Bauersachs R, Eichler I, Hoffmann J, Klocker J, Kobba J, Petzold T, Wenk H, Grundmann R. Antikoagulation mit Argatroban bei vaskulären und endovaskulären Operationen und Interventionen und Verdacht auf heparininduzierte Thrombozytopenie Typ II (HIT II). Gefäßchirurgie. 2014;7(DOI 10.1007/s00772-014-1413-z):667-74.
  31. Prins MH, Lensing AW, Brighton TA, Lyons RM, Rehm J, Trajanovic M, Davidson BL, Beyer-Westendorf J, Pap AF, Berkowitz SD, Cohen AT, Kovacs MJ, Wells PS, Prandoni P. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematol. 2014:http://dx.doi.org/10.1016/
  32. Bauersachs RM. Managing venous thromboembolism with novel oral anticoagulants in the elderly and other high-risk patient groups. Eur J Intern Med. 2014 Jun 24.2014/06/29.
  33. Bauersachs R. Edoxaban: A New Oral Direct Factor Xa Inhibitor for the Prevention and Treatment of Thromboembolic Disorders. Clin Invest. 2014;4(7):619-39.
  34. Prins MH, Lensing AW, Bauersachs R, van Bellen B, Bounameaux H, Brighton TA, Cohen AT, Davidson BL, Decousus H, Raskob GE, Berkowitz SD, Wells PS. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J. 2013 Sep 20;11(1):21.2013/09/24.
  35. Lee AY, Bauersachs R, Janas MS, Jarner MF, Kamphuisen PW, Meyer G, Khorana AA. CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients. BMC Cancer. 2013 Jun 13;13(1):284.2013/06/15.
  36. Huisman MV, Klok FA. Diagnostic management of acute deep vein thrombosis and pulmonary embolism. J Thromb Haemost. 2013 Mar;11(3):412-22.2013/01/09.
  37. Hach-Wunderle V, Bauersachs R, Gerlach HE, Eberle S, Schellong S, Riess H, Carnarius H, Rabe E. Postthrombotic Syndrome Three Years after Deep Venous Thrombosis in the TULIPA PLUS Registry. J Vasc Surg. 2013;57(1):5-12.
  38. Farge D, Debourdeau P, Beckers M, Baglin C, Bauersachs RM, Brenner B, Brilhante D, Falanga A, Gerotzafias GT, Haim N, Kakkar AK, Khorana AA, Lecumberri R, Mandala M, Marty M, Monreal M, Mousa SA, Noble S, Pabinger I, Prandoni P, Prins MH, Qari MH, Streiff MB, Syrigos K, Bounameaux H, Buller HR. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost. 2013 Dec 8.2012/12/12.
  39. Debourdeau P, Farge D, Beckers M, Baglin C, Bauersachs RM, Brenner B, Brilhante D, Falanga A, Gerotzafias GT, Haim N, Kakkar AK, Khorana AA, Lecumberri R, Mandala M, Marty M, Monreal M, Mousa SA, Noble S, Pabinger I, Prandoni P, Prins MH, Qari MH, Streiff MB, Syrigos K, Buller HR, Bounameaux H. International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer. J Thromb Haemost. 2013 Dec 8.2012/12/12.
  40. Omran H, Bauersachs R, Rubenacker S, Goss F, Hammerstingl C. The HAS-BLED score predicts bleedings during bridging of chronic oral anticoagulation. Results from the national multicentre BNK Online bRiDging REgistRy (BORDER). Thromb Haemost. 2012 Jul;108(1):65-73.2012/04/27.
  41. Bauersachs RM, Gogarten W, Hach-Wunderle V, Harenberg J, Krauspe R, Lindhoff-Last E, Leschke M, Moser M, Mouret P, Im Namen der Rivaroxaban Konsensus Gruppe, Osterhues H-H, Spannagl M, Waydhas C, Haas S. Perioperatives Management der Antikoagulation mit Rivaroxaban. Klinikarzt. 2012;41(9):418–25.
  42. Bauersachs R. Clinical presentation of deep vein thrombosis and pulmonary embolism. Best Practice & Research Clinical Haematology. 2012;25:1-9.
  43. Rabe T, Luxembourg B, Ludwig M, Dinger J, Bauersachs R, Rott H, Mueck AO, Albring C. Contraception and Thrombophilia – A statement from the German Society for Gynecological Endocrinology and Reproductive Medicine (DGGEF e.V.) and the Professional Association of German Gynaecologists BVF e.V.). Reproduktionsmed Endokrinol 2011;8(Special Issue 1):20-62.
  44. Huppert P, Adili F, Bauersachs R. Die S3-Leitlininen zur Diagnostik und Therapie der peripheren arteriellen Verschlusskrankheit Hesssisches Ärzteblatt. 2010;71(2):85-108.
  45. Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010 Dec 23;363(26):2499-510.2010/12/07.
  46. Décousus H, Leizorovicz A, Bauersachs R, Brenner B, Laporte S, Middeldorp S, Mismetti P, Prandoni P, Richard-Lordereau I. Fondaparinux for the treatment of superfical-vein thrombosis in the legs N Engl J Med. 2010;363(13):1222-32.
  47. Bauersachs R. Treatment of venous thromboembolism during pregnancy. Thrombosis Research. 2009;123(Suppl. 1):S45-S50.
  48. Bauersachs RM, Manolopoulos K, Hoppe I, Arin MJ, Schleussner E. The 'ART' behind the clot: solving the mystery. J Thromb Haemost. 2007 Feb;5(2):438-9.
  49. Bauersachs RM, Dudenhausen J, Faridi A, Fischer T, Fung S, Geisen U, Harenberg J, Herchenhan E, Keller F, Kemkes-Matthes B, Schinzel H, Spannagl M, Thaler CJ. Risk stratification and heparin prophylaxis to prevent venous thromboembolism in pregnant women. Thromb Haemost. 2007 Dec;98(6):1237-45.
  50. Bauersachs R, Alban S. Perioperative bridging with fondaparinux in a woman with antithrombin deficiency. Thromb Haemost. 2007 Mar;97(3):498-9.
  51. Alexy T, Nemeth N, Wenby RB, Bauersachs RM, Baskurt OK, Meiselman HJ. Effect of lanthanum on red blood cell deformability. Biorheology. 2007;44(5-6):361-73.
  52. Spyropoulos AC, Bauersachs RM, Omran H, Cohen M. Periprocedural bridging therapy in patients receiving chronic oral anticoagulation therapy. Curr Med Res Opin. 2006 Jun;22(6):1109-22.
  53. Schleussner E, Bauersachs R. Schwangerschaftskomplikationen bei Thrombophilie: Wann ist der Einsatz von NMH gerechtfertigt? Vascular Care. 2006;11(6).
  54. Luxembourg B, Bauersachs R. Malignom und Thrombose: eine wechselseitige klinische Beziehung. Vasa. 2005;34(4):225-34.
  55. Heidrich H, Rogatti W, Altmann E, et al. [DRG-based cost analysis of inpatient conservative treatment of stage III/IV peripheral arterial occlusive disease]. Vasa. 2003;32(4):235-40.
  56. Schellong SM, Gerlach HE, Tebbe U, Haas S, Melzer N, Abletshauser C, Sieder C, Bramlage P, Riess H, Bauersachs R. Certoparin versus UFH to prevent venous thromboembolic events in the very elderly patient: An analysis of the CERTIFY study. Thromb Res. 2011 Nov;128(5):417-21.
  57. Bauersachs RM. [Stenting of the femoral artery: the angiologist's perspective]. Hamostaseologie. 2003;23(2):71-3.
  58. Bauersachs R, Lindhoff-Last E. Anticoagulation of pregnant women with mechanical heart valves using low-molecular-weight heparin. Arch Intern Med. 2003;163(22):2788-9.
  59. Landgraf H, Bauersachs R, Bergau L, et al. Air travel thrombosis 2001. Vasa. 2002;31(1):68-70.
  60. Duprez D, Allegra C, Bauersachs R, et al. Vascular centers in Europe. Results of a panel discussion at the 14th Meeting of the European Chapter of the International Union of Angiology (Cologne, Germany, May 25, 2001). Int Angiol. 2002;21(1):96-8.
  61. Lindhoff-Last E, Eichler P, Stein M, Bauersachs, R et al. A prospective study on the incidence and clinical relevance of heparin-induced antibodies in patients after vascular surgery. Thromb Res. 2000;97(6):387-93.
  62. Bauersachs RM, Lindhoff-Last E, Ehrly AM. [Ambulatory treatment of an acute pulmonary artery embolism in fresh thigh vein thrombosis using low-molecular-weight heparin]. Dtsch Med Wochenschr. 1999;124(49):1485-8.
  63. Schopohl B, Leirmann D, Pohlit LJ, Bauersachs, R et al. 192IR endovascular brachytherapy for avoidance of intimal hyperplasia after percutaneous transluminal angioplasty and stent implantation in peripheral vessels: 6 years of experience. Int J Radiat Oncol Biol Phys. 1996;36(4):835-40

Weitere Informationen

Klinik für Gefäßmedizin

Angiologie Grafenstraße 9
64283 Darmstadt

Tel.: 06151 - 107 4401
Fax: 06151 - 107 4429



Prof. Dr. med. Rupert Bauersachs

Tel.: 06151 - 107 4401

[von der FOCUS-Ärzteliste 2018 als Top-Mediziner empfohlen]


Angiologische Ambulanz
Tel.: 06151 - 107 4444

Forschung & Publikationen

Studien und Veröffentlichungen

Darmstädter Angiologischer Arbeitskreis